Background
==========

Treatment with urodilatin (URO; ANP-95-126), a kidney derived natriuretic peptide, may be beneficial in patients with incipient acute renal failure after cardiac surgery \[[@B1]\]. The findings about mechanisms regulating endogenous production and renal excretion of URO are controversial. Recent evidence suggests that urinary excretion of urodilatin (V~URO~U) is increased in patients after uncomplicated cardiac surgery and positively correlated with blood pressure \[[@B2]\].

Objective
=========

To determine the effects of different perfusion pressures on urine flow (VU), urinary excretion of sodium (V~Na~U), potassium (V~k~U) and urodilatin (V~URO~U) and the concentration of urodilatin in the perfusate (P~URO~) in isolated perfused rat kidneys.

Materials and methods
=====================

Kidneys from Sprague-Dawley rats were perfused for 180 min with constant perfusion pressures (80 mmHg (*n* = 4); 120 mmHg (*n* = 4)) in a closed circuit system. Samples were taken every 30 min. The concentration of urodilatin in urine and perfusate were determined by a radioimmuno-assay for raturodilatin (rURO: Immundiagnostik, Bensheim, Germany) not cross-reacting with rBNP, rCNP, rCDD/ANP-99-126 or hURO.

Results
=======

Mean VU, V~Na~U, V~k~U and V~URO~U were significantly higher with a perfusion pressure of 120 mmHg than with 80 mmHg (all: *P* \< 0.05); *P*~URO~ did not change significantly.

Conclusion
==========

Our data suggest that renal perfusion pressure and consequently mean arterial blood pressure are determinants of V~URO~U. Additionally, our data underline the importance of perfusion pressure for adequate renal function; this may be especially relevant for patients at risk to develop acute renal failure after cardiac surgery.
